Strongly


An expression of the live unlimited spirit, stories and voices of the MDA community

Clinical Trial Alert: Observational Study to Identify Biomarkers in Individuals Receiving Radicava for ALS

Researchers at Mitsubishi Tanabe Pharmaceutical America (MTPA) are seeking individuals living with amyotrophic lateral sclerosis (ALS) to participate in a six-month observational study. This study is designed to identify biomarkers to serve as quantifiable, biological, non-clinical measures of Radicava (edaravone) effects on ALS. Observational measures might include assessment of vitals; blood and urine collection; safety assessments; use . . .

Read More

Clinical Trial Alert: Phase 3 Study of Zilucoplan in Individuals With Generalized Myasthenia Gravis

Researchers at Ra Pharmaceuticals (now part of UCB BioSciences) are seeking individuals living with generalized myasthenia gravis (gMG) to participate in a phase 3 study to confirm safety, tolerability, and efficacy of the investigational drug Zilucoplan. This therapy may improve muscle function by blocking the autoimmune reaction that destroys the junction between nerves and muscles in . . .

Read More

FDA Approves Sarepta Therapeutics’ Amondys 45 for Treatment of DMD Amenable to Skipping Exon 45

On Feb. 25, the US Food and Drug Administration (FDA) granted accelerated approval to casimersen (Amondys 45) for the treatment of Duchenne muscular dystrophy (DMD) in patients amenable to skipping exon 45. It is the fourth exon-skipping, disease-modifying drug to treat DMD, the most common childhood form of muscular dystrophy. The drug is administered by intravenous . . .

Read More

Clinical Trial Alert: Phase 3 Study of Rozanolixizumab in Individuals With Generalized Myasthenia Gravis

Researchers at UCB BioSciences are seeking individuals living with generalized myasthenia gravis (gMG) to participate in a phase 3 study. The objective of the study is to confirm the clinical efficacy and to assess safety and tolerability of rozanolixizumab. The therapy may help reduce the typical signs and symptoms of gMG, which are caused by autoantibodies . . .

Read More

MDA Welcomes Dr. Don Wood as its New President and CEO

Steve Jobs said, “The only way to do great work is to love what you do.” And MDA’s new president and CEO, Donald S. Wood, PhD, surely loves what he does. “The mission of this organization has been a lifelong passion for me,” Dr. Wood says. After receiving his doctorate in Physiology from Washington State . . .

Read More

How Expedited Drug Approval Impacts the Neuromuscular Disease Treatment Landscape

The urgency of the COVID-19 pandemic has transformed the drug-development landscape, driving rapid development, US review, and, in one case, new therapeutic approval. To bring critical drugs to market, the US Food and Drug Administration (FDA) is utilizing a special emergency program announced in April 2020 to accelerate approval of promising coronavirus therapies, an initiative . . .

Read More

MDA’s 2021 Advocacy Plan

2021 is a new year: The country has a new administration, and a new Congress has been sworn in. What isn’t new is MDA’s commitment to working tirelessly in Washington, DC, to transform the lives of people living with neuromuscular diseases (NMDs). Here’s a sneak peek at some of the issues we’ll be working on . . .

Read More

MDA Let’s Play Community Spotlight: NegaGrier

Jeff Shaw, program manager for MDA Let’s Play, MDA’s online gaming and streaming community, is part of a team that leads Saturday Game Nights on Twitch, celebrity streamer events for MDA, tournaments with great teams and players, and steadfast support and discussion on the MDA Let’s Play Discord server channel. Among our many great friends . . .

Read More

Research Study Alert: Survey on the Mental Health Experience of Parents and Guardians of Children With DMD

Researchers at the University of Pittsburgh invite parents and guardians of children with Duchenne muscular dystrophy (DMD) to participate in a study that investigates whether they utilize mental health resources and if they have encountered any barriers to accessing such resources.  For this study, researchers at the University of Pittsburgh will ask participants to take a . . .

Read More

Research Study Alert: LGMD2I Natural History Study

Researchers at ML Bio Solutions are seeking individuals living with limb-girdle muscular dystrophy type 2I (LGMD2I, LGMD R9-FKRP-related) to participate in a 12-month natural history study. The objective of this observational study is to identify appropriate endpoints that will be used in the phase 3 clinical trial of BBP-418 (ribitol). Data gathered may include: Fine-needle muscle biopsy . . .

Read More